Dynamic early biomarkers predict outcomes in pediatric Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis
Pediatric Investigation · 18.08.2026
DOI: 10.1002/ped4.70071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Investigation, online erschienen am 18.08.2026. Verfasst von Feifei Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hematologic Diseases Beijing Pediatric Research Institute Beijing Children's Hospital Capital Medical University National Center for Ch…. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Importance Pediatric Epstein–Barr virus (EBV)‐associated hemophagocytic lymphohistiocytosis (HLH) is a life‐threatening disorder, and early identification of poor responders is critical to improving survival. However, no convenient clinical tools exist to predict individual prognosis using dynamic biomarkers during early treatment.
Objective
To investigate the predictive value of early dynamic changes in plasma biomarkers and to develop a prognostic model for children with EBV‐HLH.
Methods
This retrospective study enrolled 60 newly diagnosed pediatric EBV‐HLH patients. We analyzed the longitudinal changes in plasma EBV‐DNA (pEBV‐DNA), ferritin, and cytokine levels during the etoposide‐based induction first‐line therapy. Independent prognostic factors were identified using Cox multivariate regression and LASSO, followed by the construction of a prognostic nomogram. Model performance was evaluated through area under the curve (AUC), decision curve analysis, and internal cross‐validation.
Results
Multivariate analysis identified positive pEBV‐DNA at week 2 (w2) and low decreases in ferritin (ΔFerritin.w2) and interferon (IFN)‐γ (ΔIFN‐γ.w2) as independent predictors of adverse outcomes. A nomogram integrating these three variables demonstrated a superior AUC of 0.834 (vs. 0.677 for pEBV‐DNA.w2 alone, P = 0.003). The model successfully stratified patients into low‐ and high‐risk groups with significantly different 3‐year event‐free survival (84.8% vs. 33.3%, P < 0.001).
Interpretation
The proposed model, based on dynamic plasma biomarkers, provides a promising tool for the early risk stratification of pediatric EBV‐HLH. Composed of pEBV‐DNA, ΔFerritin, and ΔIFN‐γ at w2, this nomogram can effectively identify patients at high risk of first‐line treatment failure. Given the exploratory nature of this study, these findings require further validation in larger, independent cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Hematologic Diseases Beijing Pediatric Research Institute Beijing Children's Hospital Capital Medical University National Center for Children's Health Beijing China.
- National Key Discipline of Pediatrics Capital Medical University Beijing China.
- Key Laboratory of Major Diseases in Children Ministry of Education Beijing China.
- Department of Hematology Beijing Children's Hospital Capital Medical University National Center for Children's Health Beijing China.
Zitieren
APA
Liu, F., Zhang, Q., Chen, S., Zhao, Y., Wang, D., Lian, H., Ma, H., Wang, T., Zhang, R., & Li, Z. (2026). Dynamic early biomarkers predict outcomes in pediatric Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis. Pediatric Investigation. https://doi.org/10.1002/ped4.70071
Vancouver
Liu F, Zhang Q, Chen S, Zhao Y, Wang D, Lian H, et al. Dynamic early biomarkers predict outcomes in pediatric Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis. Pediatric Investigation. 2026. doi:10.1002/ped4.70071
BibTeX
@article{Liu2026,
author = {Liu, Feifei and Zhang, Qing and Chen, Sitong and Zhao, Yunze and Wang, Dong and Lian, Hongyun and Ma, Honghao and Wang, Tianyou and Zhang, Rui and Li, Zhigang},
title = {Dynamic early biomarkers predict outcomes in pediatric Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis},
journal = {Pediatric Investigation},
year = {2026},
doi = {10.1002/ped4.70071}
}
EUVIMED